# US 2013/0273101 A1 · Vaccine for inducing an improved immune reaction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0273101 A1
- Document ID: US20130273101A1
- Status: Published application
- Kind: A1
- Application number: 13/995,188
- Filed: 2011-12-17
- Published: 2013-10-17
- Earliest claimed: 2010-12-18
- Assignees: Eyegene, Inc.
- Inventors: Yang Je Cho; Na Gyong Lee; Jin Wook Jang; Kwang Sung Kim; Won Il Yoo
- Web page: https://patentgrep.com/patent/US20130273101A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/0018: {Combination vaccines based on acellular diphtheria-tetanus-pertussis}
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 39/07: Bacillus
- A61K 39/095: Neisseria
- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/25: Varicella-zoster virus
- A61K 39/29: Hepatitis virus
- A61K 39/292: {Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/22: for herpes viruses
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- C12N 2710/16634: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16734: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A method for inducing immunity to an antigen in a subject, the method comprising:
administering to the subject a pharmaceutically effective amount of a vaccine composition comprising:
a pathogen-derived antigen selected from a group consisting of influenza virus antigen, Mycobacterium tuberculosis antigen, HBV (Hepatitis B virus) antigen, Bacillus anthracis antigen, Varicella virus antigen, HAV (Hepatitis A virus) antigen, HCV (Hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, HSV (Herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheria antigen, Bordetella pertussis antigen and Clostridium tetani antigen;
a deacylated non-toxic LOS (Lipooligosaccharide); and
a pharmaceutically acceptable carrier.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the Mycobacterium tuberculosis antigen is at least one antigen selected from a group consisting of 65 kD heat shock protein (HSP65), antigen 85A (Ag85A), antigen 85B, antigen 85C, ESAT-6, Des protein, MPT32, MPT51, MPT63, MPT64, HspX and Phosphate binding protein 1.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the Mycobacterium tuberculosis antigen is at least one antigen selected from a group consisting of antigen 85A (Ag85A), ESAT-6, HspX and Phosphate binding protein 1.

### Claim 38 (depends on 35)

The method according to claim 35, wherein the influenza virus antigen is envelope glycoprotein HA or NA.

### Claim 39 (depends on 38)

The method according to claim 38, wherein influenza virus antigen is the envelope glycoprotein HA.

### Claim 40 (depends on 35)

The method according to claim 35, wherein the non-toxic LOS is detoxificated by deacylation of lipid A via alkaline treatment to LPS (lipopolysaccharide).

### Claim 41 (depends on 35)

The method according to claim 35, wherein the non-toxic LOS has a molecular weight in a range of 1,500-10,000 Da.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the non-toxic LOS has a molecular weight in a range of 2,000-4,000 Da.

### Claim 43 (depends on 35)

The method according to claim 35, wherein the non-toxic LOS is derived from E. coli (Escherichia coli).

### Claim 44 (depends on 35)

The method according to claim 35, wherein the pharmaceutical composition further comprises an immunoadjuvant selected from the group consisting of a Group II element, a Group IV element, an aluminum salt thereof, a hydrate salt thereof, and a combination thereof, wherein the Group II element is selected from the group consisting of Mg, Ca, Sr, Ba, Ra, and a combination thereof, and the Group IV element is selected from the group consisting of Ti, Zr, Hf, Rf and a combination thereof.

### Claim 45

A method for preparing maturated dendritic cells, comprising incubating immatured dendritic cells with a deacylated non-toxic LOS (Lipooligosaccharide).

### Claim 46 (depends on 45)

The method according to claim 45, wherein the non-toxic LOS is detoxificated by deacylation of lipid A via alkaline treatment to LPS (lipopolysaccharide).

### Claim 47 (depends on 45)

The method according to claim 45, wherein the non-toxic LOS has a molecular weight in a range of 1,500-10,000 Da.

### Claim 48 (depends on 47)

The method according to claim 47, wherein the non-toxic LOS has a molecular weight in a range of 2,000-4,000 Da.

### Claim 49 (depends on 45)

The method according to claim 45, wherein the non-toxic LOS is derived from E. coli (Escherichia coli).
